Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study
Open Access
- 12 November 2024
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (5) , 600-605
Abstract
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. Results All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. Conclusion Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents.Keywords
Funding Information
- Bayer (Grant VITH-4)
This publication has 35 references indexed in Scilit:
- Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agentsAJO International, 2024
- Age-Related Macular DegenerationJAMA, 2024
- Comparison of intraocular pressure measured by iCare tonometers and Goldmann applanation tonometerCanadian Journal of Ophthalmology, 2022
- Rebound tonometry by iCare 200 (IC200): comparison with Tono-Pen in the operating room and Goldmann applanation in the clinicJournal of American Association for Pediatric Ophthalmology and Strabismus, 2021
- Agreement of Intraocular Pressure Measurement of Icare ic200 with Goldmann Applanation Tonometer in Adult Eyes with Normal CorneaOphthalmology Glaucoma, 2021
- The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and GlaucomaOphthalmology, 2019
- The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A reviewSurvey of Ophthalmology, 2018
- Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needleGraefe's Archive for Clinical and Experimental Ophthalmology, 2010
- Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti–Vascular Endothelial Growth Factor AgentsAmerican Journal of Ophthalmology, 2008
- Effect of Inverted Body Position on Intraocular PressureAmerican Journal of Ophthalmology, 1984